INVESTIGATOR PROTOCOL AGREEMENT PAGEInvestigator Protocol Agreement • May 22nd, 2019
This study will not commence without the prior written approval of a properly constituted Institutional Review Board (IRB). No changes will be made to the study protocol without the prior written approval of the sponsor and the IRB, except where necessary to eliminate an immediate hazard to the patient.
INVESTIGATOR PROTOCOL AGREEMENT PAGEInvestigator Protocol Agreement • November 10th, 2024
INVESTIGATOR PROTOCOL AGREEMENTInvestigator Protocol Agreement • March 22nd, 2024
Title: A SU2C Catalyst® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab (Keytruda®) with vitamin D receptor agonist Paricalcitol (Zemplar®) in Patients with Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response (with no further improvement in their tumor)
INVESTIGATOR PROTOCOL AGREEMENT PAGEInvestigator Protocol Agreement • April 12th, 2015
This study will not commence without the prior written approval of a properly constituted Institutional Review Board (IRB). No changes will be made to the study protocol without the prior written approval of the sponsor and the IRB, except where necessary to eliminate an immediate hazard to the patient.
